Cargando…
A Doxorubicin-Glucuronide Prodrug Released from Nanogels Activated by High-Intensity Focused Ultrasound Liberated β-Glucuronidase
The poor pharmacokinetics and selectivity of low-molecular-weight anticancer drugs contribute to the relatively low effectiveness of chemotherapy treatments. To improve the pharmacokinetics and selectivity of these treatments, the combination of a doxorubicin-glucuronide prodrug (DOX-propGA3) nanoge...
Autores principales: | Besse, Helena C., Chen, Yinan, Scheeren, Hans W., Metselaar, Josbert M., Lammers, Twan, Moonen, Chrit T. W., Hennink, Wim E., Deckers, Roel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7355552/ https://www.ncbi.nlm.nih.gov/pubmed/32532061 http://dx.doi.org/10.3390/pharmaceutics12060536 |
Ejemplares similares
-
Ultrasound-directed enzyme-prodrug therapy (UDEPT) using self-immolative doxorubicin derivatives
por: Roemhild, Karolin, et al.
Publicado: (2022) -
A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
por: Haisma, H. J., et al.
Publicado: (1992) -
Challenges in nanomedicine clinical translation
por: Metselaar, Josbert M., et al.
Publicado: (2020) -
A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug
por: de Graaf, M, et al.
Publicado: (2002) -
A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer
por: Houba, P H J, et al.
Publicado: (2001)